On one hand, there are opportunities for profits from investing in Nanoviricides Inc.(OTC:NNVC). On the other, there is a pattern of slow decline that has been going on since May. Back in May, the share price reached $1.60, yet failed to keep that level. Two weeks ago, it reached $1.01 per share. This week, levels around $1.20 are at hand. Jumps and slumps overall. 
No news at hand, though. Regular trading days, during which smart speculative investors could make money. The last time to hear from Nanoviricides was the announcement from Monday 15th this month. A press release about its leading anti-HIV drug candidate announced it has achieved a long-term anti-HIV effect. No wonder, that session opened at $1.10 and closed at $1.25 per share. Nothing after that. Well, not exactly nothing. In terms of SEC filings, there is a long list of Form 4, coming almost on a daily basis, including one name in them – Anil Diwan, the President of the company.
On a related subject, SEC filings of Nanoviricides might be overflowing with Form4, but lack another important file – the quarterly statement. The last to come out was the 10-Q with an end-date March 31st this year. If traders want to know what the financial condition of the company is, they obviously have to wait a bit more. For the moment, these is the data at hand to look at:
- $7.7 million in cash; [BANNER]
- $8.2 million in total current assets;
- $809k in total current liabilities;
- $21.9 million in accumulated deficit;
- $0 in revenues;
- $2.5 million in net loss;
Nothing out of the ordinary at the end of March. Actually, not a bad ratio of assets to liabilities. Yet, also a net loss not to go overlooked. All in all, as mentioned, there are opportunities for profits. However, the lack 10-Q for the second quarter, the lack of a notification of late filing, coupled with the constant ups and downs in the share price, brings a level of uncertainty which not all long-term investors might be comfortable with.
